Guru Sonpavde, MD, Associate Professor of Medicine
Director, Urologic Oncology, UAB Comprehensive Cancer Center answers the question Why would sequencing VEGF and PD-1 inhibition be a better option than combination therapy in Kidney Cancer.
Why would sequencing VEGF and PD-1 inhibition be a better option than combination therapy
